Gross Margin % is calculated as gross profit divided by its revenue. Moderna's Gross Profit for the
three
months ended in Dec. 2023 was $1,884 Mil. Moderna's Revenue for the
three
months ended in Dec. 2023 was $2,813 Mil. Therefore, Moderna's Gross Margin % for the quarter that ended in Dec. 2023 was 66.97%.
The historical rank and industry rank for Moderna's Gross Margin % or its related term are showing as below:
MRNA'
s Gross Margin % Range Over the Past 10 Years
Min: 30.52 Med: 78.28 Max: 97.08
Current: 30.52
During the past 8 years, the highestGross Margin % of Moderna was 97.08%. The lowest was 30.52%. And the median was 78.28%.
MRNA's Gross Margin % is ranked worse than 78.64% of 735
companies
in the Biotechnology industry
Industry Median: 59.4
vs MRNA: 30.52
Moderna had a gross margin of 66.97% for the quarter that ended in Dec. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Moderna was 0.00% per year.
Moderna Gross Margin % Historical Data
The historical data trend for Moderna's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Moderna's Gross Margin %
For the Biotechnology subindustry, Moderna's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moderna's Gross Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moderna's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Moderna's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Moderna (NAS:MRNA) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Moderna had a gross margin of 66.97% for the quarter that ended in Dec. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Moderna Gross Margin % Related Terms
Thank you for viewing the detailed overview of Moderna's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRNA has been successfully added to your 